Onkologie. 2024:18(1):32-38 | DOI: 10.36290/xon.2024.007

HER-2 low breast cancer

Adam Paulík
Lékařská fakulta, Univerzita Karlova v Hradci Králové
Klinika onkologie a radioterapie, Fakultní nemocnice Hradec Králové

HER-2 low breast cancer is newly established term of completely heterogeneous subgroup of breast cancer sharing one common phenotype which is low to moderate expression of HER-2 protein and not meeting criteria for HER-2 positivity. The specific attribute of this subgroup is high responsiveness to antibody-drug conjugates (ADC´s) that can cause bystander killing effect (ADC´s of the 3rd generation - especially T-DXd) in comparison to older ADC´s lacking this disposition (T-DM1) and to monoclonal antibodies (trastuzumab, pertuzumab, margetuximab) with almost zero efficacy due to the absence of oncogenic HER-2 signalling in HER-2 low tumours. HER-2 ultra-low subtype is defined as ≤ 10% of infiltrating cancer cells showing incomplete and faint/weak membrane staining with proven efficacy of T-DXd as well. Due to the frequent HER-2 heterogenity during the course of time the re-biopsy approach is of crucial importance to reassess the up-to-date HER-2 status enabling subsequent treatment with T-DXd.

Keywords: breast cancer subtypes, HER-2 low, ADC (antibody-drug conjugate), trastuzumab-deruxtecan (T-DXd), bystander effect, intersticial pneumonitis.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Paulík A. HER-2 low breast cancer. Onkologie. 2024;18(1):32-38. doi: 10.36290/xon.2024.007.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Comprehensive molecular portraits of human breast tumours. The Cancer Genome Atlas Network. Nature. 2012;490:61-70.
    2. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Arch Pathol Lab Med. 2018;142:1364-1382. Go to original source... Go to PubMed...
    3. Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1. Go to original source... Go to PubMed...
    4. Tarantino P, Jin Q, Tayob N, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8:1177-1183. Go to original source... Go to PubMed...
    5. Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 2022;24(1):22. Go to original source... Go to PubMed...
    6. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151-1161.Další literatura u autora a na www.onkologiecs.cz Go to original source... Go to PubMed...
    7. Tarantino P, Jin Q, Tayob N, et al. 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer. Ann Oncol. 2022;33:S124. Go to original source...
    8. Peiffer DS, Zhao F, Chen N, et al. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023;9(4):500-510. Go to original source... Go to PubMed...
    9. Bao KKH, Sutanto L, Tse SSW, et al. The association of ERBB2-low expression with the efficacy of cyclin-dependent kinase 4/6 inhibitor in hormone receptorepositive, ERBB2-negative metastatic breast cancer. JAMA Netw Open. 2021;4:e213313. Go to original source... Go to PubMed...
    10. Miglietta F, Griguolo G, Bottosso M, et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer. 2021;7(1):137. Go to original source... Go to PubMed...
    11. Tarantino P, Gandini S, Nicolò E, et al. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer Oxf Engl. 2022;163:35-43. Go to original source... Go to PubMed...
    12. Bar Y, Dedeoglu A, Fell G, et al. Dynamic HER-2 low status among patients with triple-negative breast cancer (TNBC) -the impact of repeat biopsies. Presented at ASCO 2023 Annual meeting. Go to original source...
    13. Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020;38:444-453. Go to original source... Go to PubMed...
    14. Gianni L, Llado A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:1131-1137. Go to original source... Go to PubMed...
    15. U.S. National Library of Medicine. Available from: https: //clinicaltrials.gov/ct2/show/results/NCT01828021.
    16. Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: Three-year outcomes from the phase III KRISTINE Study. J Clin Oncol. 2019;37:2206-2216. Go to original source...
    17. Cortes J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143-1154. Go to original source... Go to PubMed...
    18. Mosele MF, Lusque A, Dieras V, et al. LBA1 Unraveling the mechanism of action and resistence to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial. Ann Oncol. 2022;33:S123. Go to original source...
    19. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20. Go to original source... Go to PubMed...
    20. Tarantino P, Hamilton E, Tolaney SM, et al. HER-2 low breast cancer: Pathological and clinical landscape. Journal of Clinical of Oncology. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. PMID: 32330069. Go to original source... Go to PubMed...
    21. Molinelli CH, Jacobs F, Marchiò C, et al. HER2-low breast cancer: Where are we? Breast Care (Basel). 202217(6):533-545. doi: 10.1159/000527391. Epub 2022 Oct 6. PMID: 36590146; PMCID: PMC9801403. Go to original source... Go to PubMed...
    22. Nader-Marta G, Molinelli CH, Debien V, et al. Antibody-drug conjugates: the evolving filed of targeted chemotherapy for breast cancer treatment. Ther Adv Med Oncol. 2023;15:1-24. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.